

Open Globe Injury

Urgent Care Emergency Department Inpatient

Center for Clinical Excellence

If suspected

open globe injury,

contact Ophthalmology

immediately

Open Globe symptoms include:

- Bullous subconjunctival hemorrhage
- Peaked and / or minimally reactive pupil
- Extrusion of ocular contents
- Mechanism of injury concerning for ocular or orbital penetration
- History of trauma and significant pain or reduction in visual acuity

*ED Antibiotics:

- Age ≥ 6 months:
 - Levofloxacin 10mg/kg/dose
- Age < 6months:
 - o Vancomycin 15mg/kg/dose AND
 - Ceftazidime 50mg/kg/dose

High Infection Risk:

- Intraocular foreign body
- Dirty wound
- Delayed closure
- Lens capsule violation
- Injury in rural setting

Discharge Criteria:

- Patient stable
- Tolerating PO abx
- Cleared by Ophthalmology

Concern for open globe injury **Consult Ophthalmology** (if at UC, call via PCTC prior to transfer) **Consider Level 2 Trauma** Acute management


- Apply rigid eye shield
- **Emesis control**
- Pain management
- Elevate head of bed, if no contraindications

If significant agitation can be avoided:

- Place IV
- ED antibiotics*
- Tetanus (if not UTD)

If high suspicion for globe injury:

- Do not apply significant pressure to the globe or eyelids
- Do not administer ocular meds



Discharge home

Levofloxacin for a total of 7 days Close follow-up with Ophthalmology

Oral Levofloxacin

CPP-ED-IP-UC Open Globe Injury Clinical Pathway Published: 12/14/2021; Revised: 4/24/2024

References

•	Benchmark protocols for managing eye trauma. Available at: https://eye.hms.harvard.edu/eyeinsights/2014-april/benchmark-protocols-managingeye-trauma.

Pathway Team & Process

Content Development Team

Clinical Pathways Program:

Medical Director – Emergency Medicine:

Ophthalmology
Hilliary Inger, MD

Medical Director - Associate Chief Quality Officer,

Berkeley Bennett, MD, MS

Center for Clinical Excellence:

Ryan Bode, MD, MBOE

Members
Inpatient Pharmacy

Leaders

Troy Kienzle, PharmD

Medical Director – Clinical Informatics & Emergency

Medicine:

Infectious Disease

Joshua Watson, MD

Laura Rust, MD, MPH

Emergency Medicine

Berkeley L. Bennett MD, MS Morgan Wurtz, MD

Business & Development Manager:

Rekha Voruganti, MBOE, LSSBB

Program Coordinator:

Tahje Brown, MBA

Clinical Pathway Approved:

Medical Director - Associate Chief Quality Officer,

Center for Clinical Excellence:

Ryan Bode, MD, MBOE

Advisory Committee Date: January, 2020

Origination Date: *January, 2020* Last Revision Date: *August, 2023*

Clinical Pathway Development

This clinical pathway was developed using the process described in the NCH Clinical Pathway Development Manual Version 6, 2022. Clinical Pathways at Nationwide Children's Hospital (NCH) are standards which provide general guidance to clinicians. Patient choice, clinician judgment, and other relevant factors in diagnosing and treating patients remain central to the selection of diagnostic tests and therapy. The ordering provider assumes all risks associates with care decisions. NCH assumes no responsibility for any adverse consequences, errors, or omissions that may arise from the use or reliance on these guidelines. NCH's clinical pathways are reviewed periodically for consistency with new evidence; however, new developments may not be represented, and NCH makes no guarantees, representations, or warranties with respect to the information provided in this clinical pathway.

Copyright © 2023. Nationwide Children's Hospital. All rights reserved. No part of this document may be reproduced, displayed, modified, or distributed in any form without the express written permission of Nationwide Children's Hospital.

For more information about our pathways and program please contact: ClinicalPathways@NationwideChildrens.org